Biofrontera Inc. (BFRI): Nasdaq/NYSE listing notice — Biofrontera receives Nasdaq deficiency notice for bid price below $1.00 for 34 days

Biofrontera Inc.

Nasdaq notice on Dec 31, 2025: common stock not compliant with Listing Rule 5550(a)(2) due to closing bid below $1.00.
Company has 180 calendar days, until June 30, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, company may qualify for second 180-day period by meeting other continued listing standards and indicating intent to cure via reverse stock split.
Failure to cure could lead to delisting; company plans to monitor and consider available options.
No immediate impact on trading; Biofrontera common trades on Nasdaq under symbol BFRI.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 34 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Biofrontera Inc. filing history →

Source: SEC EDGAR

accession 0001493152-26-000823

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.